|ReadCoor and WAVE Life Sciences Initiate Research Collaboration|
Collaboration aims to unlock next generation stereopure nucleic acid targets with novel FISSEQ technologies
Over the next two years, ReadCoor and WAVE have agreed to develop a cell map of the mouse brain and to leverage it to characterize stereopure nucleic acid candidates in specific regions, cell types, and subcellular compartments of the brain. This agreement marks the first major industry collaboration for ReadCoor and increases the number of platform collaborations aimed at unlocking next generation targets for WAVE.
ReadCoor’s proprietary FISSEQ (Florescent In-Situ Sequencing) platform is designed to provide critical spatial data by combining next generation sequencing and three-dimensional imaging. This unique in-situ sequencing technique is expected to provide meaningful insight of disease state, treatment effects, and outcomes at the molecular level. WAVE’s drug development platform is designed to enable the development of stereopure nucleic acid therapeutics, with optimized efficacy, stability, safety, and specificity. By leveraging ReadCoor’s technology, WAVE expects to increase its ability to identify transcriptome changes at the regional, cellular, and subcellular levels within the central nervous system and to expand its existing discovery capabilities for next generation candidate development.
“At WAVE, one of our founding principles is that you cannot truly
optimize nucleic acid therapeutics using mixtures of molecules. We
believe the same is true when targeting biology using mixtures of cell
ReadCoor is leading the next generation of omics by delivering the first panomic spatial sequencing platform to the global audience of researchers, clinicians, pharma and diagnostics companies, and ultimately patients. It is accomplishing this with Fluorescent In-situ Sequencing (FISSEQ), a fundamental new technology, which simultaneously integrates high throughput sequencing, and three-dimensional morphometric analysis. This uniquely powerful platform is expected to revolutionize the next phase in understanding the panomic landscape and may introduce vast new opportunities for important and meaningful clinical insight.
Forward Looking Information
This press release contains forward-looking statements, including
statements relating to the distinguishing features of WAVE’s drug
development platform and of ReadCoor’s sequencing technology, and the
potential benefits that each party anticipates deriving from the
collaboration. These statements may be identified by words such as
“believe,” “expect,” “may,” “plan,” “potential,” “will” and similar
expressions, and are based on current beliefs and expectations. These
statements involve risks and uncertainties that could cause actual
results to differ materially from those reflected in such statements,
including, as it relates to WAVE, risks and uncertainties associated
with drug development, the regulatory approval process and
commercialization, the development and acceptance of therapies with new
technologies, as well as other risks and uncertainties that are
described in the Risk Factors section of WAVE’s most recent annual or
quarterly report filed with the